We are live on ! Find out more
MRVI icon

Maravai LifeSciences
MRVI

216 hedge funds and large institutions have $3.72B invested in Maravai LifeSciences in 2022 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 92 increasing their positions, 76 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

134% more call options, than puts

Call options by funds: $6.21M | Put options by funds: $2.65M

21% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 76

2.41% more ownership

Funds ownership: 97.31% → 99.72% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less funds holding

Funds holding: 235 → 216 (-19)

17% less capital invested

Capital invested by funds: $4.51B → $3.72B (-$789M)

41% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 39

Holders
216
Holders Change
-19
Holders Change %
-8.09%
% of All Funds
3.64%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
23
Increased
92
Reduced
76
Closed
39
Calls
$6.21M
Puts
$2.65M
Net Calls
+$3.56M
Net Calls Change
-$7.32M

Top Buyers

Rank Fund Capital Flow
1
Massachusetts Financial Services
Massachusetts Financial Services
Massachusetts
+$118M
2
American Century Companies
American Century Companies
Missouri
+$75.9M
3
Renaissance Technologies
Renaissance Technologies
New York
+$30.5M
4
AIM
Artemis Investment Management
United Kingdom
+$29.1M
5
Prudential Financial
Prudential Financial
New Jersey
+$23.4M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$172M
2
CIP
Champlain Investment Partners
Vermont
-$36.8M
3
N
Natixis
France
-$35.3M
4
Millennium Management
Millennium Management
New York
-$17.6M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$12.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
AAP
201
Arax Advisory Partners
Colorado
$3K – – –
HR
202
Howe & Rusling
New York
$3K +$285 +9 +9%
Lazard Asset Management
203
Lazard Asset Management
New York
$2K – – –
Loomis, Sayles & Company
204
Loomis, Sayles & Company
Massachusetts
$2K – – –
PCG
205
Private Capital Group
Connecticut
$2K – – –
PI
206
PEAK6 Investments
Illinois
$1.16K +$2.95K +93 New
MFT
207
Moisand Fitzgerald Tamayo
Florida
$1K -$1.27K -40 -50%
Jones Financial Companies
208
Jones Financial Companies
Missouri
$1K -$1.11K -35 -55%
National Bank of Canada
209
National Bank of Canada
Quebec, Canada
$1K – – –
RA
210
Rise Advisors
New York
$1K – – –
PLU
211
Performa Ltd (US)
South Carolina
$1K +$1.58K +50 New
Bank of Montreal
212
Bank of Montreal
Ontario, Canada
$654 +$218K +6,892 +42%
N
213
Natixis
France
– -$35.3M -1,000,000 Closed
HM
214
HealthCor Management
New York
– -$7.05M -200,000 Closed
JF
215
Jump Financial
Illinois
– -$4.51M -128,021 Closed
PHP
216
Parkman Healthcare Partners
Connecticut
– -$2.73M -77,389 Closed
QT
217
Quantbot Technologies
New York
– -$2.44M -69,305 Closed
SSA
218
Schonfeld Strategic Advisors
New York
– -$2.18M -61,800 Closed
LOAMS
219
Lombard Odier Asset Management (Switzerland)
Switzerland
– -$1.3M -37,000 Closed
MFS
220
Mirabella Financial Services
United Kingdom
– -$1.25M -35,439 Closed
VF
221
Virtu Financial
New York
– -$1.24M -35,042 Closed
SEC
222
Seven Eight Capital
New York
– -$1.13M -31,928 Closed
WP
223
Woodline Partners
California
– -$1.08M -30,517 Closed
TCM
224
Tributary Capital Management
Nebraska
– -$1.05M -29,900 Closed
Walleye Capital
225
Walleye Capital
New York
– -$858K -24,320 Closed
7 8
9
10 11

MRVI Hedge Fund Activity: Q2 2022 in Review

216 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q2 2022, worth a combined $3.72B — down 17% from $4.51B a quarter earlier.

Sellers outnumbered buyers: 39 funds closed out of MRVI and 23 opened new positions — a net loss of 16 holders — while 76 trimmed existing stakes and 92 added.

The largest buyer was Massachusetts Financial Services, adding an estimated $118M. The largest seller was Fidelity Investments, cutting an estimated $172M.

  • 216 institutional investors held Maravai LifeSciences (MRVI) as of Q2 2022, down from 235 in Q1 2022.
  • Funds reported $3.72B of Maravai LifeSciences stock for Q2 2022, down 17% quarter-over-quarter.
  • 23 funds opened new Maravai LifeSciences positions in Q2 2022 and 39 closed out, a net change of -16 holders.
  • The largest Maravai LifeSciences buyer in Q2 2022 was Massachusetts Financial Services, an estimated $118M added.
  • The largest Maravai LifeSciences seller in Q2 2022 was Fidelity Investments, an estimated $172M sold.

Based on aggregated 13F filings for Q2 2022.